自然杀伤T细胞在临床和前期的使用中的目前进展。
Current Developments in the Preclinical and Clinical use of Natural Killer T cells.
发表日期：2023 Jan
作者：
Christina Kratzmeier, Sasha Singh, Emmanuel B Asiedu, Tonya J Webb
来源：
BIODRUGS
摘要：
自然杀伤T细胞（NKT细胞）在先天免疫反应和适应性免疫反应之间发挥着关键作用，并在体内稳态调节中起着重要作用。本文讨论了NKT细胞在病毒感染和癌症治疗中作为生物药物的潜力。NKT细胞正被研究用于预后生物标志物、免疫佐剂和细胞治疗。历史上，NKT细胞的临床效用受到了其在血液中的低频、命名的差异和体外扩展的挑战的阻碍。然而，该领域的最新进展促进了几种基于NKT细胞的临床前和临床策略的发展。这些新的进展为成功实施基于NKT细胞的方法治疗人类疾病铺平了道路。©2022作者，在Springer Nature Switzerland AG的授权下。
Natural killer T (NKT) cells play a pivotal role as a bridge between the innate and the adaptive immune response and are instrumental in the regulation of homeostasis. In this review, we discuss the potential for NKT cells to serve as biodrugs in viral infections and in cancer. NKT cells are being investigated for their use as a prognostic biomarker, an immune adjuvant, and as a form of cellular therapy. Historically, the clinical utility of NKT cells was hampered by their low frequency in the blood, discrepancies in nomenclature, and challenges with ex vivo expansion. However, recent advances in the field have permitted the development of several NKT cell-based preclinical and clinical strategies. These new developments pave the way for the successful implementation of NKT cell-based approaches for the treatment of human disease.© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.